Cubist Systematic Strategies LLC Invests $4.51 Million in Amicus Therapeutics, Inc. $FOLD

Key Points

• Cubist Systematic Strategies LLC has invested approximately $4.51 million in Amicus Therapeutics, acquiring 552,025 shares, which represents about 0.18% ownership of the company.
• Analyst ratings for Amicus Therapeutics show eight analysts assigned a "Buy" rating while two rated it as "Hold", with an average target price of $16.22.
• Amicus Therapeutics has a market capitalization of $2.47 billion and its stock trading currently at $8.02, showing a 1-year low of $5.51 and a high of $12.65.

Cubist Systematic Strategies LLC purchased a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 552,025 shares of the biopharmaceutical company's stock, valued at approximately $4,505,000. Cubist Systematic Strategies LLC owned approximately 0.18% of Amicus Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Virtus Fund Advisers LLC bought a new position in Amicus Therapeutics in the fourth quarter valued at approximately $29,000. PNC Financial Services Group Inc. raised its position in Amicus Therapeutics by 211.4% during the first quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 3,497 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Amicus Therapeutics during the first quarter worth $53,000. GF Fund Management CO. LTD. bought a new stake in Amicus Therapeutics during the fourth quarter worth $59,000. Finally, GAMMA Investing LLC raised its position in Amicus Therapeutics by 1,610.8% during the first quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company's stock worth $61,000 after acquiring an additional 7,007 shares in the last quarter.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Morgan Stanley raised shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research report on Thursday, July 17th. Wall Street Zen downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, August 30th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Amicus Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $16.00.

Amicus Therapeutics Stock Up 1.5%

FOLD traded up $0.12 during mid-day trading on Wednesday, reaching $8.01. 645,641 shares of the stock were exchanged, compared to its average volume of 3,861,950. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.29 and a current ratio of 3.21. The stock has a market capitalization of $2.47 billion, a PE ratio of -66.49 and a beta of 0.55. The company has a 50 day moving average price of $6.83 and a two-hundred day moving average price of $7.03. Amicus Therapeutics, Inc. has a 1 year low of $5.51 and a 1 year high of $12.65.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.